| Field | Specification |
|---|---|
| Target | |
| Alternative names | RNA-binding protein Musashi homolog 2;Musashi-2;MSI2; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human GluR2+GluR3 |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 18G36 is a rabbit monoclonal antibody that recognizes GRIA2/3 in human, mouse and rat samples and is validated for Western blot and immunoprecipitation.
| Target | GRIA2/3 (UniProt P42262/P42263) |
|---|---|
| Clone | 18G36 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Observed MW | 99, 101 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunoprecipitation | 1:100 |
Immunogen
Synthetic peptide based on the sequence of human gluR2+GluR3.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
